THCT · As filed with the SEC

THC Therapeutics income statement, by quarter

The statement as THC Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONSOLIDATED STATEMENT OF OPERATIONS · USD, except per-share amounts

USD, except per-share amounts	Q4 FY24^† 3 months ended Jul 31, 2024	Q3 FY24 3 months ended Apr 30, 2024	Q2 FY24 3 months ended Jan 31, 2024	Q1 FY24 3 months ended Oct 31, 2023
Revenue	0^†	0	0	0
Cost of Revenue	0^†	0	0	0
Gross profit	0^†	0	0	0
Operating expenses
Professional Fees	80,524^†	148,415	30,738	6,960
Consulting fees	—	—	—	0
Labor and Employee Benefits	(281,332)^†	222,000	46,938	46,937
Selling, General and Administrative Expense	222,716^†	9,283	7,475	1,321
Total operating expenses	21,908^†	379,698	85,151	55,218
Loss from operations	(21,908)^†	(379,698)	(85,151)	(55,218)
Other income (expense)
Non-Operating Income (Expense)	(173,060)^†	502,657	(467,154)	12,113
Interest Expense	0^†	0	0	0
Interest expense	(86,756)^†	(18,337)	(19,670)	(19,380)
Total other income (expense)	(259,816)^†	484,320	(486,824)	(7,267)
Net income (loss)	(281,724)^†	104,622	(571,975)	(62,485)
Basic loss per common share	—	—	0.06	0.00
Basic weighted average common shares outstanding	—	—	32,865,868	32,746,149
Earnings Per Share (Basic)	—	0.00	—	—
Weighted Average Shares Outstanding	—	38,334,816	—	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.